ImpediMed (IPD) investor relations material

Strategic growth initiatives and equity raising

• Up to $15.2 million equity raising targets capital-light expansion into high-value markets and partial debt prepayment, aiming for operating cashflow breakeven in FY28, assuming full exercise of options.

• SOZO® platform leverages FDA-cleared BIS technology for fluid status and body composition analysis, with strong clinical evidence, regulatory approvals, and reimbursement coverage across BCRL, Heart Health, and Weight Management.

• Expansion into US Heart Health ($600M TAM) and Weight Management ($425M TAM) markets follows SOZO® Pro launch, with first sales in Heart Health and a robust pipeline of leads and prospects.

• Over 93% national US payer coverage achieved in Q2 FY26, supporting accelerated pipeline conversion and long-term growth runway.

• Equity raising comprises a two-tranche institutional placement and a share purchase plan, with attaching and follow-on options, subject to shareholder approval.

Financial performance and cost optimization

• FY26 YTD revenue reached $11.0 million, with annual recurring revenue at $14.1 million and gross margins of 87%.

• 138 SOZO® units sold globally YTD, with an 8% average price increase for renewed US contracts.

• $5.0 million partial debt prepayment and $5.7 million annualized cost reduction, including headcount and administrative consolidation, target a pro forma net cash position of $5.9 million.

• Operating cashflow breakeven anticipated in H2 FY28, driven by revenue growth, cost base optimization, and financial deleverage.

• Q3 FY26 operating cash outflow was $4.5 million, with a cash balance of $12.7 million at quarter end.

Market positioning and growth drivers

• SOZO® platform is installed in 172 of 500 leading US cancer centers and 17 of 25 top US cancer hospitals, with a durable recurring revenue model and high gross margins.

• Over 700 devices in the active sales pipeline, representing $35 million TCV, and only 10% penetration in breast cancer sites of care.

• SOZO® Pro enables low-friction expansion into Heart Health and Weight Management via existing BCRL customer relationships, with contracts and IT infrastructure already established in 17 of 20 top IDNs.

• Clinical guidelines and reimbursement tailwinds support adoption, with bioimpedance now named in three landmark 2025 guidelines for objective measurement in weight loss management.

• Attractive customer economics and ROI for providers, with rapid payback periods and scalable deployment across multiple departments and care sites.